PMID- 29735278
OWN - NLM
STAT- MEDLINE
DCOM- 20180806
LR  - 20180828
IS  - 1095-6859 (Electronic)
IS  - 0090-8258 (Linking)
VI  - 150
IP  - 1
DP  - 2018 Jul
TI  - Bilateral salpingectomy with delayed oophorectomy for ovarian cancer risk
      reduction: A pilot study in women with BRCA1/2 mutations.
PG  - 79-84
LID - S0090-8258(18)30842-4 [pii]
LID - 10.1016/j.ygyno.2018.04.564 [doi]
AB  - OBJECTIVE: Risk-reducing salpingo-oophorectomy (RRSO) reduces ovarian cancer risk
      in BRCA1/2 mutation carriers, but the adverse effects of the associated
      early-onset surgical menopause are problematic. Despite suggestive evidence, no
      data demonstrate whether bilateral salpingectomy alone lowers the risk of
      developing ovarian cancer in BRCA mutation carriers. We conducted a pilot study
      of bilateral salpingectomy with delayed oophorectomy (BS/DO) in BRCA mutation
      carriers to determine the safety and acceptability of the procedure. METHODS: In 
      this prospective, multicenter, non-randomized pilot study, pre-menopausal BRCA1/2
      mutation carriers aged 30 to 47years chose screening, RRSO, or BS/DO. For those
      undergoing BS/DO, the delayed oophorectomy was recommended at age 40years for
      BRCA1 and age 45years for BRCA2 patients. We compared surgical and psychosocial
      outcomes between time points and between arms. RESULTS: Of the 43 patients
      enrolled, 19 (44%) chose BS/DO, 12 (28%) chose RRSO, and 12 (28%) chose
      screening. The cohort was 37% BRCA1 carriers and 63% BRCA2 carriers. One serous
      tubal intraepithelial carcinoma (STIC) was found in an RRSO patient, and no cases
      of occult ovarian cancers were found. There were no surgical complications.
      Twelve months after surgery, responses on the Cancer Worry Scale indicated
      decreased worry in the BS/DO (P<0.0001) and RRSO (P=0.01) arms, while responses
      on the State Anxiety Inventory indicated decreased anxiety in the BS/DO arm
      (P=0.02) compared with preoperative responses. CONCLUSIONS: In this pilot study, 
      BRCA mutation carriers who underwent bilateral salpingectomy had no
      intraoperative complications, were satisfied with their procedure choice, and had
      decreased cancer worry and anxiety after the procedure.
CI  - Copyright (c) 2018. Published by Elsevier Inc.
FAU - Nebgen, Denise R
AU  - Nebgen DR
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, United States. Electronic address: 
      dnebgen@mdanderson.org.
FAU - Hurteau, Jean
AU  - Hurteau J
AD  - Division of Gynecologic Oncology, NorthShore University Health System, Pritzker
      School of Medicine, University of Chicago, Evanston, IL, United States.
FAU - Holman, Laura L
AU  - Holman LL
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, United States.
FAU - Bradford, Andrea
AU  - Bradford A
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, United States.
FAU - Munsell, Mark F
AU  - Munsell MF
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, United States.
FAU - Soletsky, Beth R
AU  - Soletsky BR
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, United States.
FAU - Sun, Charlotte C
AU  - Sun CC
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, United States.
FAU - Chisholm, Gary B
AU  - Chisholm GB
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, United States.
FAU - Lu, Karen H
AU  - Lu KH
AD  - Department of Gynecologic Oncology and Reproductive Medicine, The University of
      Texas MD Anderson Cancer Center, Houston, TX, United States.
LA  - eng
GR  - P30 CA016672/CA/NCI NIH HHS/United States
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, N.I.H., Extramural
DEP - 20180504
PL  - United States
TA  - Gynecol Oncol
JT  - Gynecologic oncology
JID - 0365304
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA1 protein, human)
RN  - 0 (BRCA2 Protein)
RN  - 0 (BRCA2 protein, human)
SB  - IM
MH  - BRCA1 Protein/*genetics/metabolism
MH  - BRCA2 Protein/*genetics/metabolism
MH  - Female
MH  - Humans
MH  - Ovarian Neoplasms/*genetics/pathology/*surgery
MH  - Ovariectomy/*methods
MH  - Pilot Projects
MH  - Prospective Studies
MH  - Risk Reduction Behavior
MH  - Salpingectomy/*methods
EDAT- 2018/05/08 06:00
MHDA- 2018/08/07 06:00
CRDT- 2018/05/09 06:00
PHST- 2018/01/24 00:00 [received]
PHST- 2018/04/17 00:00 [revised]
PHST- 2018/04/18 00:00 [accepted]
PHST- 2018/05/08 06:00 [pubmed]
PHST- 2018/08/07 06:00 [medline]
PHST- 2018/05/09 06:00 [entrez]
AID - S0090-8258(18)30842-4 [pii]
AID - 10.1016/j.ygyno.2018.04.564 [doi]
PST - ppublish
SO  - Gynecol Oncol. 2018 Jul;150(1):79-84. doi: 10.1016/j.ygyno.2018.04.564. Epub 2018
      May 4.